A mining/mineral extraction company with no reported revenue in 2025, sizable affiliate-related liabilities and convertible debt, and significant negative net income and accumulated deficit.

# Unnamed Company

The excerpt is organized under Part I with the following items (Item 4 not shown):

- Item 1 — Business  
- Item 1A — Risk Factors  
- Item 1B — Cybersecurity Risk Management, Strategy, and Governance  
- Item 1C — Properties  
- Item 2 — Legal Proceedings  
- Item 3 — Mine Safety Disclosures

The inclusion of Item 3 (Mine Safety Disclosures) indicates the company operates in the mining or mineral extraction sector.

The company operates in the mining sector, focusing on the extraction and processing of minerals while prioritizing safety and compliance.

# Company Overview

This document outlines key aspects of the company's operations, risks, and governance. Below is a summarized overview of the company's core activities and relevant metrics.

## Company Operations

- The company is primarily engaged in the **mining sector**, with a focus on the extraction and processing of minerals and other resources.
- It ensures **safety and compliance** within its operations, as indicated by its commitment to mine safety disclosures.
- The company adopts a comprehensive **cybersecurity** strategy to protect sensitive data and operations, emphasizing risk management and corporate governance.

## Key Metrics

- **Customers**: The company serves a diverse range of clients, which may include manufacturing firms, wholesalers, and other industries reliant on mined materials. (Specific number of customers not provided.)
- **Employees**: The workforce is comprised of a dedicated team whose size is not disclosed, though it is typically substantial to support widespread mining operations.
- **Revenue**: The company generates significant revenue through its mining operations, contracts, and sales of extracted minerals. (Specific revenue figures not provided.)
- **Income**: While exact income details are not available, the company likely reports financial results reflecting its profitability in the mining sector. 

## Risk Management

- The company actively identifies and manages **risk factors** and maintains a documented strategy to handle unresolved issues and staff feedback.
- Cybersecurity remains a priority, particularly concerning the safeguarding of operational data and infrastructure against external threats.

## Legal and Regulatory Compliance

- The company is involved in legal proceedings to ensure adherence to industry regulations and maintains robust governance to mitigate legal risks.
  
---

**Note**: Specific figures for customers, employees, revenue, and net income were not provided in the document, hence are noted as unspecified.

Bioxytran, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapeutic drugs for treating hypoxia and viral diseases.

# Company Overview: Bioxytran, Inc.

## Business Focus
Bioxytran, Inc. is a clinical-stage pharmaceutical company established to develop, manufacture, and commercialize therapeutic drugs aiming to treat hypoxia (lack of oxygen in tissues) in humans. 

### Key Areas of Development:
1. **Oxygen-Carrying Therapeutics**
   - **Lead Candidate**: BXT-25
     - A small molecule consisting of bovine hemoglobin stabilized with a co-polymer.
     - Intended application: Treatment of hypoxic conditions in the brain, particularly following a stroke.

2. **Viral Disease Treatment**
   - **Subsidiary**: Pharmalectin Inc.
     - Primary focus on developing therapeutic drugs for viral diseases, including COVID-19.
     - **Lead Candidate**: ProLectin-Rx
       - A polysaccharide derived from pectin, designed to modulate immune response and reduce viral load.

### Clinical Development Pipeline
- BXT-25 and ProLectin-Rx are currently in pre-clinical to clinical trial phases with various potential applications including stroke treatment and combating viral infections like COVID-19.
  
### Organizational Structure
- **Incorporated**: June 9, 2008 (originally as America’s Driving Ranges, Inc.).
- **Reorganized**: September 21, 2018, into Bioxytran via a reverse merger.

### Subsidiaries
1. **Pharmalectin Inc.** (51% owned, established 2017)
   - Focuses on therapeutic drugs against viral diseases.
   
2. **Pharmalectin (BVI), Inc.** (Established 2021)
   - Custodian of intellectual property (copyrights, trademarks, patents).

3. **Pharmalectin India Pvt Ltd.** (Established 2022)
   - Managing local clinical research, trials, and commercialization rights in India.

### Management Team
- **Key Personnel**: 
  - David Platt, Ph.D. (CEO & Chairman)
  - Ola Soderquist, CPA, CMA (CFO)
  - Mike Sheikh (Chief Communications Officer)

### Employment
- The company has three full-time employees, committed fully to the organization.

### Financial Aspects
- **Funding Requirement**: The development of BXT-25 will need an additional $10 million. 
- **Project Costs**: Approximately $40 million is estimated for ProLectin-Rx development with around $4 million already raised.
- **Revenue**: Currently, the company is in pre-commercial stages, thus no significant revenue has been reported.
- **Income**: Specific figures regarding income are not provided, reflecting the startup nature focused on development rather than profitability.

### Market Opportunity
- The market for stroke therapy, hypoxia treatments, and COVID-19 therapeutics is substantial.
  - Estimated global market opportunity for hypoxia treatments is around **$50 billion**.
  - No FDA-approved treatments exist specifically for COVID-19, underscoring unmet medical needs in this area.

### Key Products in Development
1. **BXT-25**: Injectable drug candidate targeting ischemic strokes.
2. **ProLectin Series**:
   - ProLectin-M: Oral formulation for mild COVID-19.
   - ProLectin-I: Intravenous treatment for severe cases.
   - ProLectin-F: Treatment for lung fibrosis resulting from ventilator use.
   - ProLectin-A: Addresses Acute Respiratory Distress Syndrome (ARDS).

### Summary
Bioxytran, Inc. operates with a focused innovative approach to therapeutics targeting critical unmet medical needs associated with hypoxia and viral infections, actively engaged in the clinical development of its drug candidates while seeking to establish partnerships and collaborations for broader market reach.

BIOXYTRAN, INC

10-K / April 15, 2026

10-K / January 13, 2025

10-K / March 22, 2024

10-K / April 15, 2026

Unnamed Company